Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23788536 | 0.90 | LTB4R (0.32) | PPARG | |
| SCHEMBL23788479 | 0.83 | PPARG (0.32) | PPARGMEN1KMT2ACES2CES1 | |
| SCHEMBL23788643 | 0.78 | IRAK4 (0.31) | — | |
| SCHEMBL23788332 | 0.76 | — | — | |
| SCHEMBL23788330 | 0.76 | LTB4R (0.32) | — | |
| SCHEMBL23788629 | 0.75 | LTB4R (0.32) | — | |
| SCHEMBL23788601 | 0.74 | LTB4R (0.30) | — | |
| SCHEMBL23788466 | 0.74 | KDM4E (0.32) | PPARGMEN1KMT2ACES2CES1 | |
| SCHEMBL23788474 | 0.74 | IRAK4 (0.32) | — | |
| SCHEMBL23788553 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3720857-B1 | 2-OXO-5H-CHROMENO[4,3-B]PYRIDINES FOR USE IN THE TREATMENT OF HEPATITIS B | GALAPAGOS NV (BE) | 2021-09-08 | — | — | EP | disclosed |